Skip to main content
Equibles
RIGL logo

RIGL · Rigel Pharmaceuticals Inc · Metrics

Track RIGL — free

Use RIGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RIGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$47.28 +0.06 (+0.13%) At close · Sep 10
Russell 2000 member Rebalance outlook locked
Market Cap
$882.06M
Shares
18.68M

RIGL metrics

77 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$47.28
Market cap
$882.06M

Price action

20 metrics
Price change (1W)
-4.5%
Price change (30D)
+12.4%
Price change (3M)
+52.8%
Price change (6M)
+73.3%
Price change (YTD)
+10.2%
Price change (1Y)
+31.4%
Trailing year
Price change (5Y)
—
52-week high
$50.96
52-week low
$25.44
Change from 52-week high
-7.3%
Change from 52-week low
+85.6%
Annualized volatility
64.6%
Annualized volatility (3M)
44.3%
Beta
0.8
RSI (14D)
60.1
Price vs SMA 50
+11.9%
Price vs SMA 200
+29.7%
Avg volume (3M)
342,544
Relative volume
0.5
Average dollar volume
$13.77M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
18.68M

Valuation

12 metrics
P / E (TTM)
2.8
Trailing earnings · reciprocal yield 35.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.4%
P / book
2.1
reciprocal yield 48.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
11.1
reciprocal yield 9.0%
Earnings yield
36.5%

Historical valuation

8 metrics
P / E historical average (3Y)
14.5×
reciprocal yield 6.9%
P / E historical average (5Y)
14.5×
reciprocal yield 6.9%
EV / revenue historical average (3Y)
1.7×
reciprocal yield 59.3%
EV / revenue historical average (5Y)
1.9×
reciprocal yield 52.7%
EV / EBIT historical average (3Y)
9.1×
reciprocal yield 11.0%
EV / EBIT historical average (5Y)
9.1×
reciprocal yield 11.0%
EV / EBITDA historical average (3Y)
8.0×
reciprocal yield 12.5%
EV / EBITDA historical average (5Y)
8.0×
reciprocal yield 12.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
93.3%
Operating margin
31.5%
Trailing 12 months
Net margin
116.3%
Gross profit (TTM)
$60.80M
Operating profit (TTM)
$87.05M
Net income (TTM)
$321.91M
Trailing 12 months
Diluted EPS (TTM)
$16.89
FCF margin
—
Effective tax rate
-276.2%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$3.60
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$21.38

Growth

11 metrics
Revenue growth YoY
-22.6%
Year over year
Net income growth YoY
-71.0%
Revenue (TTM)
$276.79M
Trailing 12 months
EPS growth YoY
-73.2%
Shares change YoY
+7.8%
Year over year · more shares
Revenue CAGR (3Y)
+34.8%
Revenue CAGR (5Y)
+22.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
75.7%
Return on assets
61.8%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
$89.70M
Free cash flow (TTM)
—
Quick ratio
1.8
Interest coverage
15.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$60.82M
Total assets
$521.07M
Total debt
$45.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$79.39M
Capital expenditures (TTM)
—
R&D (TTM)
$43.67M
SG&A (TTM)
$122.22M
Stock compensation (TTM)
$16.41M
R&D / revenue
15.8%
Stock compensation / revenue
5.9%

Ownership (13F)

3 metrics
13F filers
157
13F filer change QoQ
-2
Institutional ownership
88.5%

Short interest

3 metrics
Short interest
17.0%
Latest settlement · 9.1 days to cover
Days to cover
9.1d
Short-squeeze score
76 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$87,500
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1034842 CUSIP 766559702 13F (30d) 90 filings 90 filers Visit website Investor relations